Allergan Biocell textured breast implants
In July 2019 the US Food and Drug Administration (FDA) requested that Allergan recall its Allergan Natrelle BIOCELL Textured Breast Implants and Tissue Expanders, from sale worldwide. Allergan agreed and a global recall of the products followed.
The FDA acted based on growing data that Allergan Implants are linked with patients developing a rare type of non-Hodgkin’s lymphoma described as Breast Implant Associated Anaplastic Large Cell Lymphoma, or BIA-ALCL.
The UK Medicines and Healthcare Regulatory Authority (MHRA) has provided advice to women who currently have Allergan implants, and who may be affected by the recall.
Recalled products list
As of October 2021, the MHRA reported that 88 women in the UK had been diagnosed with BIA-ALCL linked to breast implant surgery. As stated by the MHRA, BIA-ALCL is a rare condition, however, as with all cancers if this condition develops it is important for patients to seek medical help quickly. It is therefore vital that all healthcare professionals and patients who have implants know about it.
As it stands the MHRA’s specialist committee does not recommend that patients with Allergan implants have them removed and advises people who are worried about developing BIA-ALCL to seek advice from their GP or surgeon.
Despite its low risk, some women with Allergan implants in the UK may remain anxious about developing BIA-ALCL and may wish to access removal and/or replacement surgery, but are unable to do so due to lack of funds.
Options for redress
Hausfeld London is working with a team in London and the US, investigating ways in which women can bring a legal claim if the fact of Allergan's decision to recall their product has left them anxious about retaining their implants. Recent legal developments in France may give women a new route to justice and compensation beyond the routes that have traditionally been available – for example through contract law or under the Consumer Protection Act 1987.
Action in the Netherlands
On 1 December 2021, on behalf of the Dutch women’s rights organization Bureau Clara Wichmann, Hausfeld Advocaten in Amsterdam held Allergan liable and requested that it compensate all damages suffered by women in the Netherlands with Allergan biocell breast implants. If Allergan refuses, we will start a collective action on behalf of Bureau Clara Wichmann for the 60.000 women in the Netherlands who have received Allergan biocell breast implants. This lawsuit is an initiative of Bureau Clara Wichmann with the support of Stichting SVS/Meldpunt Klachten Siliconen and the Breast Cancer Association of the Netherlands.
What are you asking me to do?
If you are interested in hearing more, please provide your contact details using the form below or by emailing AllerganGroup@hausfeld.com. We will then be able to keep you updated on our investigations. If you reside in the Netherlands, more information can be found on the dedicated Dutch claim website 'Siliconen Zaak' which has its own enquiry form.
How will this work?
We are currently carrying out all legal and investigatory work around a possible group claim on a no win no fee basis. The Hausfeld Team are specialists in group and collective claims and we are working with experienced legal experts in this field.
We will provide regular updates as our investigations continue and add your name to a list of individuals who have also been affected by this issue. If you wish to withdraw your name at any point you can contact Hausfeld by emailing AllerganGroup@hausfeld.com.
Have you been affected?
If you believe you have been affected by the recall of Allergan implants and have concerns regarding BIA-ALCL, please contact us at AllerganGroup@hausfeld.com or complete the enquiry form below and one of our team will be in touch.
For those affected in the Netherlands, the dedicated Dutch claim website 'Siliconen Zaak' offers additional information.